Who Paid My Doc
Jafar Alzubi
Interventional Cardiology Baltimore, MD Medical Doctor
NPI 1124542014 CMS profile 7236945
201 E University Pkwy, Baltimore, MD 21218
General payments
$5,055
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Jafar Alzubi of Baltimore, MD is reported in the CMS Open Payments database as having received $5,055 across 69 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 39th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
6 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $1,814 | 26 | |
| 2024 | General | $1,747 | 5 | |
| 2023 | General | $298 | 10 | |
| 2022 | General | $189 | 9 | |
| 2021 | General | $584 | 12 | |
| 2020 | General | $424 | 7 |
Beside peers
- Jafar Alzubi
- Interventional Cardiology median
- Middle half of Interventional Cardiology
- National median
In program year 2025, general payments to Jafar Alzubi were reported at $1,814. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.
Show as a table
| Year | Jafar Alzubi | Interventional Cardiology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $1,097 | $329–$3,048 | $163 |
| 2020 | $424 | $473 | $161–$1,480 | $114 |
| 2021 | $584 | $677 | $233–$1,827 | $132 |
| 2022 | $189 | $978 | $333–$2,724 | $149 |
| 2023 | $298 | $1,136 | $382–$2,986 | $160 |
| 2024 | $1,747 | $1,181 | $395–$3,326 | $164 |
| 2025 | $1,814 | $1,092 | $366–$3,019 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 1 drugPart D claims
13
Drug cost
$8,569
Branded share of claims
100%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Entresto Sacubitril/Valsartan | Brand | 13 | $8,569 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.
Records
69 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Interventional Cardiology in Maryland
Vinay Satwah
Interventional Cardiology · Greenbelt, MD
Aloke Finn
Interventional Cardiology · Baltimore, MD
Michael Chen
Interventional Cardiology · Rockville, MD
John Wang
Interventional Cardiology · Baltimore, MD
Steven Hearne
Interventional Cardiology · Salisbury, MD
Amir Najafi
Interventional Cardiology · Bel Air, MD
Related records
Interventional Cardiology in Maryland
Practitioners in the same specialty and state, ranked by reported value.
All Interventional Cardiology
Everyone recorded under this specialty, nationwide.
Doctors in Maryland
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.